These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 19022670

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S, Wu W, Shih NY, George Njoroge F.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4760-3. PubMed ID: 19596195
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 15; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 6. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Chen KX, Bogen S, Nair L, Tong X, Chase R, Hart A, Agrawal S, Pichardo J, Prongay A, Cheng KC, Girijavallabhan V, Piwinski J, Shih NY, Njoroge FG.
    J Med Chem; 2009 Jan 22; 52(2):336-46. PubMed ID: 19102654
    [Abstract] [Full Text] [Related]

  • 7. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Madison V, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2151-5. PubMed ID: 20226659
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

  • 13. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS.
    Acc Chem Res; 2008 Oct 11; 41(10):1252-63. PubMed ID: 18681464
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pyrrolidine-5,5-trans-lactams. 4. Incorporation of a P3/P4 urea leads to potent intracellular inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ, Amphlett EM, Andrews DM, Bamborough P, Carey SJ, Johnson MR, Jones PS, Mills G, Parry NR, Somers DO, Stewart AJ, Skarzynski T.
    Org Lett; 2003 Nov 27; 5(24):4627-30. PubMed ID: 14627400
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Phosphorous acid analogs of novel P2-P4 macrocycles as inhibitors of HCV-NS3 protease.
    Pompei M, Francesco ME, Koch U, Liverton NJ, Summa V.
    Bioorg Med Chem Lett; 2009 May 01; 19(9):2574-8. PubMed ID: 19328685
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.